Table 2 Approved or in-trial mucosal vaccines for other diseases
From: Mucosal immune response in biology, disease prevention and treatment
Name | Type | Characters | Targeted pathogens | ref. |
|---|---|---|---|---|
FluMist Quadrivalent | Nasal vaccine | Consists of each two strains of live attenuated influenza virus A and B, induces cross-reactive SIgA, nasal cavity as the induction site; | Influenza virus | |
FluGen’s M2SR vaccine | Nasal vaccine | Consists of both live attenuated influenza virus A and B types, deletes a portion of the M2 gene resulting in a single round of viral replication, | Influenza virus | |
Ad4-H5-Vtn | Oral/nasal vaccine | Adenovirus-vectored, encodes recombinant haemagglutinin of influenza virus, nasal cavity and rectum as the induction site; | Influenza virus | |
SynGEM | Nasal vaccine | Consists of RSV F protein with an immunostimulatory bacterium-like particle, nasal cavity as the induction site; | Respiratory syncytial virus | |
Sabin mOPV | Oral vaccine | Consists of a monovalent live attenuated poliovirus, gut as the induction site; | Poliovirus | |
CysVac2/Advax | Nasal vaccine | Consists of multistage fusion protein CysVac2, Lung as the induction site; | Mycobacterium tuberculosis | |
Vivotif | Oral vaccine | Consists of a live attenuated Salmonella typhi Ty21a strain, gut as the induction site; | Salmonella typhy | |
Rotarix | Oral vaccine | Consists of a live attenuated human rotavirus RIX4414 strain, gut as the induction site; | Group A rotaviruses | |
RotaTeq | Oral vaccine | Live rotavirus strains containing recombinant surface proteins G1, G2, G3, G4 and P1(8) of human-bovine reassortant rotaviruses; | Group A rotaviruses | |
Dukoral | Oral vaccine | Consists of inactivated strains of Vibrio cholerae serotype O1 and recombinant cholera toxin B subunit, gut as the induction sites; | Vibrio cholerae | |
Vaxchora | Oral vaccine | Consists of a weakened human rotavirus RIX4414 strain, gut as the induction sites; | Vibrio cholerae |
